PRANA BIOTECHNOLOGY LTD PRAN an der Nasdaq zu ordern!

ein Biotechnologie Wert aus Australien,

In Deutschland wird der Wert auch gehandelt und als ADR Wert, an der Nasdaq!

Empfhele den Wert in großen Mengen an der Nasdaq zu ordern. Das Handelvolumen übersteigt, das der Heimatbörse, und das will was heißen!  

MELBOURNE, Australia, Mar 25, 2004 /PRNewswire-FirstCall via COMTEX/ -- Prana
Biotechnology Limited (ASX: PBT; Nasdaq: PRAN) today announced that Forbes.com
has added Prana to its list of "neurological drugs to watch," highlighting the
most promising experimental drugs to treat diseases of the brain and nervous
system.

Harvard University's Professor Ashley Bush, M.D., Ph.D., is described as a
"provocative scientist", whose approach to treating Alzheimer's Disease is
distinct from that of most big drug companies. Dr. Bush argues that copper and
zinc interact with proteins in the brain (beta-amyloid) to make them toxic.

Professor Bush has recently entered into a 10-year extension consultancy
agreement with Prana.

To obtain the article of Forbes 'Neurological Drugs to Watch', please go to:
http://www.forbes.com/2004/01/26/cx_mh_rl_neurotearsheet_print.html

About Prana:

Prana is a Melbourne-based biotechnology established in 1997 to commercialize
research into Alzheimer's disease and other major age-related degenerative
disorders (ASX: PBT; Nasdaq: PRAN). Prana's technology was discovered by the
company's researchers at prominent international institutions including
Massachusetts General Hospital at Harvard Medical School, the University of
Melbourne and the Mental Health Research Institute in Melbourne.

SOURCE Prana Biotechnology Limited



CONTACT:          Media: Ivette Almeida of The Anne McBride Co., +1-212-983-1702,

                 ext. 209, ivette.almeida@annemcbride.com, or Investor: Steven Silver of The

                 Anne McBride Co., +1-212-983-1702, ext. 212, silver@annemcbride.com, both for

                 Prana; or Company: Geoffrey Kempler, Executive Chairman, Prana Biotechnology

                 Limited, +61-3-9690-7892, gkempler@pranabio.com



URL:              http://www.pranabio.com

http://www.prnewswire.com


Copyright (C) 2004 PR Newswire.  All rights reserved.

 

Nachdem die Vorgaben in USA schon positiv waren!

PBT Kürzel an der ASX

http://www2.tradingroom.com.au/apps/qt/quote.ac?section=chart&code=PBT  

http://www2.tradingroom.com.au/news_research/index.jsp?
section=news_search&page=http%3A%2F%2Fnewsstore.f2.com.au%2Fapps%2FviewDocument.
ac%3Fsy%3Dtpl_nws%26ss%3DTPL%26docID%3DGCA00429396PBT%26backTo%3Dhttp%3A%2F%2Fwww2.
tradingroom.com.au%2Fapps%2Fqt%2Fquote.ac%3Fcode%3DPBT%26sy%3Dtpl­%26section%3Dca

Medikament zeigt Erfolge in 2. Klinischer Phase!  

In Berlin oder USA PRAN ADR WERT

in USA ist noch Kurspotential heute drin von 6.20 auf 6.80 mind. da austr. Kurs!

 

 

Interesse mit zwei ss ging nicht mehr rein!

Braucht euch nicht wundern, warum ich interessante
Werte nicht mehr poste!
Interessiert hier sowieso keinen!

Grenke und andere bekannte Namen sind hier im forum beliebter!

Und meine Werte sind auf Pushen nicht angewiesen, da meist an der Nasdaq notiert!

Da bringen die paar Umsätze aus Deutschland gar nichts.

Heute In australien 8,8 Mio
in USA am Freitag umgerechnet auf die ADRS waren es
6,11 Mio bzw. 611 TSD in 10 er Stückelung!

 

lesen bestimmt mehr Leute - lagst doch ziemlich gut in lezter Zeit

hätt ich mal auch ein paar deiner Empfehlungen kaufen sollen ... aber ich hab immo eine kleine Blockade - außerdem lese ich das Hot Stocks Forum nicht mehr besonders

RIM ist ja auch noch gut weitergelaufen


Grüßle :-)  

in Deutschland ein sehr marktenger Wert mit geringen Umsätzen. Nicht jeder hat die Möglichkeit, direkt an den Heimatmärkten zu ordern (ich z.B.). Ich lese trotzdem deine Empfehlungen !!  

Prana Biotech kauft man an der Nasda, Kürzel PRAN und ist nicht tuer in USA bei den Banken uzu ordern!

Kurs aktuell!

PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN

Real-time ECN Quote*
Last Change (%) After Hours Chg (%)** Trade Time Bid Ask
7.80  0.98 (11.16) N/A 09:50 7.80 (2) 7.90 (4)

--------------------------------------------------
Exchange QuoteLast Change (%) Trade Time Bid (size) Ask (size)
8.27  0.51 (5.81) 09:30 8.61 (4) 8.69 (50)
Latest Ticks Prev Close Open Low High
==-- 8.78 8.74 8.27 9.09
Day Volume Avg Day Vol VWAP 52 Wk Low 52 Wk High
52,015 210,800 8.7174 2.95 10.50
# of Trades Last Size Avg Trade Size P/E Ratio Market Cap (mil)
69 1,000 754 0


WKN in Deutschland für Nasdaq ist 753907  

sind ja tolle Umsätze in NJ, in Berlin aber noch keine einzige Aktie gehandelt heute  

VectorVest Stock Analysis of Prana BiotchADR as of 4/22/2004

 
Business: PRANA BIOTECHNOLOGY LTD -ADR, (PRAN) Seeks to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. The company's mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain
 
Price: PRAN closed on 4/22/2004 at $7.39 per share  
 
Value: Value is a measure of a stock's current worth.  PRAN has a current Value of $1.04 per share. Therefore, it is overvalued compared to its Price of $7.39 per share.  Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitably increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock's Price and Value always will converge.  
 
RV (Relative Value): RV is an indicator of long-term price appreciation potential. PRAN has an RV of 0.15, which is very poor on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.
 
RS (Relative Safety): RS is an indicator of risk. PRAN has an RS rating of 0.85, which is fair on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.
 
RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock's price trend. PRAN has a Relative Timing rating of 1.40, which is excellent on a scale of 0.00 to 2.00.  RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods. Once a stock's price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.  
 
VST (VST-Vector):  VST is the master indicator for ranking every stock in the VectorVest database. PRAN has a VST rating of 1.00, which is fair on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price. The efficacy of this indicator was demonstrated in a study conducted at the University of Chicago which showed that high VST stocks outperformed the S&P 500 by 583.1% over the six year period from 1996 through 2002.  
 
CI (Comfort Index): CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines. PRAN has a CI rating of 1.26, which is very good on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history. VectorVest advocates the purchase of high CI stocks.  
 
GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. PRAN has a forcasted Earnings Growth Rate of -7.00%, which VectorVest considers to be very poor. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, (7.54%).  
 
Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. PRAN has a Hold recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.  
 
Stop (Stop-Price): Stop is an indicator of when to sell a long position or cover a short position.  PRAN has a Stop of $5.56 per share. This is $1.83 below PRAN's current closing Price. A stock's Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock's fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a 'B' or 'H' recommendation if its Price is above its Stop and an 'S' recommendation if its Price is below its Stop.
 
EPS (Earnings per Share):  EPS stands for leading 12 months Earnings Per Share.  PRAN has a forecasted EPS of $-1.02 per share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.  
 
P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings.  PRAN has a P/E of -7.25. This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 36.63. P/E is computed daily using the formula: P/E = Price/EPS.  
 
EY (Earnings Yield): EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. PRAN has an EY of -13.83 percent. This is below the current average of 2.74% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price).  
 
GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. PRAN has a GPE rating of -0.97.  High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 5.84%, the operative GPE ratio is 0.34. Therefore, PRAN may be considered to be overvalued.  
 
DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. PRAN does not pay a dividend.  
 
DY (Dividend Yield): DY reflects earnings per share as a percent of Price. PRAN does not pay a dividend, so it does not have a Dividend Yield rating. . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy.  
 
DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. PRAN does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY.

 
DG (Dividend Growth Rate): Dividend Growth is a subtle yet important indicator of a company's financial performance. It also provides some insight into the board's outlook on the company's ability to increase earnings. PRAN does not pay a dividend, so it does not have a Dividend Growth rating .  
 
YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. PRAN does not pay a dividend, so it does not have a YSG rating . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for above average current income and long-term growth.  
 
Open: PRAN opened trading at a price of $7.45 per share on 4/22/2004.
 
High: PRAN traded at a High price of $8.27 per share on 4/22/2004.
 
Low: PRAN traded at a Low price of $7.18 per share on 4/22/2004
 
Close: PRAN closed trading at price $7.39 per share on 4/22/2004. (Close is also called Price in the VectorVest system)
 
Range: Range reflects the difference between the High and Low prices for the day. PRAN traded with a range of $1.09 per share on 4/22/2004.  
 
$Change: PRAN closed down 0.21 from the prior day's closing Price.  
 
%PRC: PRAN's Price changed -2.76% from the prior day's closing price.
 
Volume: PRAN traded 131,900 shares on 4/22/2004.
 
AvgVol: AvgVol is the 50 day moving average of daily volume as computed by VectorVest. PRAN has an AvgVol of 105,100 shares traded per day.
 
%Vol: %Vol reflects the percent change in today's trading volume as compared to the AvgVol. %Vol equals 100 x (Volume/AvgVol). PRAN had a %Vol of 25.50% on 4/22/2004
 
Sales: PRAN has annual sales of $
 
Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. PRAN has a Sales Growth of 177.00% per year. This is excellent. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations.  
 
Sales Per Share (SPS): PRAN has annual sales of $0.05 per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group.  
 
Price to Sales Ratio (P/S): PRAN has a P/S of 135.33. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.
 
Shares: PRAN has 5,000,000 shares of stock outstanding.
 
Market Capitalization: PRAN has a Market Capitalization of $43,000,000. Market Capitalization is calculated by multiplying price times shares outstanding.
 
Industry Group: PRAN has been assigned to the Drug (Biomedical\Genetic) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
 
Business Sector: PRAN has been assigned to the Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
 
 

laut Austr. Börse kommen news. und wird erst wieder am Mittwoch eingesetzt, oder wenn die Nachricht füher da ist. Wird also heute nacht was kommen!

die Amis haben es heute nacht nicht mitbekommen, obgleich es beie denen ja noch abends war, zu Austr. Börsenzeit.

Es gibt aber keine anhaltspunkte was es für eine Nachricht sein kann?

Nun machen kann man ohnedies nichts, weil Handel überall ausgesetzt ist! auch in USA!

schätze von der Company wird man auch nichts in Erfahrung bringen können! Noch dazu, wenn man vom Ausland aus anruft.

 

Fand ich als Erklärung in einem austr. Börsenboard!


"capital raising... typical process after share price rise, issue more shares to capitilize. Find out tomorrow, just hoipng for an issue price above .95 so as not to depress share price."

Das wäre eine plausible Erklärung!

 

Nun ist die Nachricht raus!

 

http://www2.tradingroom.com.au/news_research/...%3Dtpl%26section%3Dca

Außerdem kann er Optionen erwerben zu 8 US $

Ich hoffe der Link läßt sich aufrufen, weil diese Seite nur mit Anmeldung funktioniert
Austr. Börse!


Ist doch eine sensationelle Nachricht, der Kurs dürfte hochschießen!  

   Latest News  

--------------------------------------------------
(Printer friendly version) Prana Biotechnology $US20m placement to US health funds  


Sydney, Apr 28, 2004 (RWE via COMTEX) -- Prana Biotechnology Ltd has entered
definitive agreements with new American institutional investors for a $US20
million placement of 4 million ADRs at $US5 each.

The agreements also involved the acquisition by the investors of five-year
warrants to buy an additional 3 million ADRs at an exercise price of $US8 each,
which would raise a further $US24 million.

The transaction is to close upon shareholder approval, which is expected to be
obtained promptly.

Executive chairman Mr Geoffrey Kempler said, "These additional funds will allow
us to independently fund further trials of our MPAC technology, which has shown
early promise as a potential treatment for Alzheimer's disease in clinical
trials.

"We intend to accelerate the development of PBT-2, our 'second-generation'
product, into clinical trials planned for later this year."

Shares in Prana fell 18c to 82c today before improving to 93c.

The shares had risen from 48c last month to as high as $1.18 in April.


RWE Australian Business News

URL:              rweabn.com.au


Copyright 2004 RWEABN





SUBJECT CODE:     Australian Equities



 

Haben den Kurs der Austr. Börse genommen, aber die Nachricht kam erst heute nach Börsenschluss!

Und die Kursausssetzung hat wohl Einige nervös gemacht und gingen lieber raus!  

von den News!

Dabei habe ich die Nachrichten außer von der austral. Börse auch auf der US Seite,. sogar zum Kopieren gesucht!

na dann gute NachT!

die diskutieren über die alten Nachrichten noch!

Können die nicht Nachrichten lesen?
Muß doch auffallen, wenn ein Kurs 3 Tage ausgestzt wurde!!

Gruß
GS  

Prana to Present at Citigroup Smith Barney Biotech Showcase  


MELBOURNE, Australia, Apr 29, 2004 /PRNewswire-FirstCall via Comtex/ -- Prana
Biotechnology Limited (Nasdaq: PRAN, ASX: PBT), today announced that the Company
has been invited to present later today at Citigroup Smith Barney's second
biannual "Medtech and Biotech Bullring," in Sydney, Australia.

Geoffrey Kempler, Prana's Executive Chairman, will provide an update of Prana's
scientific and commercial milestones, including forthcoming clinical trials for
its MPAC technology, which has shown early promise as a potential treatment for
Alzheimer's disease. Mr. Kempler will highlight recent data from an extended
Phase II trial in patients with Alzheimer's disease, which was presented earlier
this month at the 8th International Springfield/Montreal Symposium on Advances
in Alzheimer's Disease.

About Prana

Prana is a Melbourne-based biotechnology established in 1997 to commercialize
research into Alzheimer's disease and other major age-related degenerative
disorders (Nasdaq: PRAN; ASX: PBT). Prana's technology was discovered by the
company's researchers at prominent international institutions including
Massachusetts General Hospital at Harvard Medical School, the University of
Melbourne and the Mental Health Research Institute in Melbourne. For more
information about Prana, please visit www.pranabio.com

SOURCE Prana Biotechnology Limited



CONTACT:          Geoffrey Kempler of Prana, +61-3-9690-7892, or

                 gkempler@pranabio.com; Media and Investor, US: Ivette Almeida,

                 ivette.almeida@annemcbride.com, or Steven Silver, silver@annemcbride.com, both

                 of Anne McBride, +1-212-983-1702 ext. 209; Media, Australia: Kate Mazoudier,

                 +61-1-3-866-4722, or kmazoudier@bcg.com.au, all for Prana Biotechnology

                 Limited



URL:              http://www.prnewswire.com

                 http://www.pranabio.com


Copyright (C) 2004 PR Newswire.  All rights reserved.




 

Und zwar kräftig!  

dieser Aktie. Das Ding ist hoch spekulativ. Hier kommt in den nächsten Tagen der Absturz schlecht hin.  

Beiträge, das machst du doch nur, weil ich aus GPC ausgestiegen bin!!

Was soll das! Mach nur weiter so, wenn du nichts vernünftiges zu sagen hast, dann bleibe hier weg!

Du Frusti!  

bzw. sauer sein, weil andere das nicht tun und einfach schlauer sind?
Geteilter Verlust ist in dem Fall ja nicht halber Verlust :)
Hat Mr.Grenke-Zeichen eigentlich auch mal irgendwen auf das Risiko bei seiner
GPC 200 hingewiesen?
Oder macht man das nur bei Aktien, die andere Leute vorstellen?  

haben ... denk ich

aber ehrlich gesagt halte ich das Kursziel für absolut übertrieben